SCHEMBL14750

SCHEMBL14750

CC(N)CCCc1cccc(C(C)(C)C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 3/20 0.49
HTR2A P28223 2/20 0.49
HTR2B P41595 2/20 0.49
TAAR1 Q96RJ0 3/20 0.40
SLC6A2 P23975 4/20 0.39
SIGMAR1 Q99720 3/20 0.39
SLC6A4 P31645 3/20 0.39
SLC6A3 Q01959 2/20 0.39
MAOA P21397 1/20 0.39
CYP2A6 P11509 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
FDFT1 P37268 1/20 0.39
BCHE P06276 1/20 0.39
BACE1 P56817 1/20 0.39
CYP2D6 P10635 2/20 0.38
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12061425 0.86 HTR2C (0.44) HTR2CHTR2AHTR2BTAAR1SLC6A2
SCHEMBL15785053 0.83 HMGCR (0.38) HTR2CHTR2AHTR2BOPRM1KCNH2
SCHEMBL12075814 0.81 TAAR1 (0.42) HTR2CHTR2AHTR2BTAAR1SLC6A2
SCHEMBL6991319 0.81 BCHE (0.40) HTR2CHTR2AHTR2BTAAR1SLC6A2
SCHEMBL12062277 0.80 TAAR1 (0.53) TAAR1MAOACYP2A6CYP2D6CYP1A2
SCHEMBL27810300 0.80 HTR2A (0.42) HTR2CHTR2AHTR2BTAAR1SLC6A2
SCHEMBL12061422 0.78 MAOA (0.52) TAAR1MAOADRD2HRH1HTR1D
SCHEMBL5321597 0.78 TAAR1 (0.56) TAAR1SLC6A2SIGMAR1SLC6A4SLC6A3
SCHEMBL26030893 0.78 LPL (0.46) TAAR1BCHEHTT
SCHEMBL11396987 0.78 TP53 (0.46) HTR2ATAAR1SIGMAR1MAOABCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME BioVersys AG (CH) 2016-02-04 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
WO-2011047319-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same MPO, LPO, CAT HTR2C 4749/4885HTR2A 4773/4885HTR2B 4779/4885
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MPO, LPO, CAT HTR2C 4749/4885HTR2A 4773/4885HTR2B 4779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.